Comparison
Octreotide vs. Pasireotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
83150-76-9
396091-73-9
Molecular weight
1019.24 g/mol
1047.21 g/mol
Half-life
1.7 h
no data
Sequence
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)no data
Mechanism of action
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
1
of which in humans
4
1
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Octreotide and Pasireotid?
- Octreotide is classified as "Research other", while Pasireotid is classified as "Research other". Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Octreotide or Pasireotid?
- The highest available evidence level is "Human RCT" for Octreotide and "Human RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Octreotide and Pasireotid in Germany and the United States?
- Germany: Octreotide — Prescription, Pasireotid — Prescription. United States: Octreotide — Prescription, Pasireotid — Prescription. These are factual summaries with source and review date on the individual pages.